A Medsky Topics feed composed of posts covering recent news related to GLP-1 Agonists such as Semaglutide (Ozempic, Wegovy, Rybelsus), Liraglutide (Victoza), and Tirzepatide (Zepbound, Mounjaro) Powered by @medsky.social
Feed on Bluesky
www.wesa.fm
Pa. Medicaid to stop paying for use of Ozempic-type meds to cover weight loss next month
Pennsylvania has quietly moved to limit access next year to popular weight-loss drugs like Ozempic and Wegovy for residents covered by Medical Assistance, the stateās Medicaid plans.
nbcnews.to
Novo Nordisk still sees potential for GLP-1 drugs for Alzheimerās, despite trial setback
GLP-1 drugs, which include Ozempic and Wegovy, have becomeĀ one of the most closely watched experimental approachesĀ for slowing Alzheimerās ā a disease with few treatment options.
www.healio.com
Mechanistic effects of semaglutide reduce albuminuria, preserve glomerular filtration
HOUSTON ā Semaglutide demonstrated efficacy in reducing albuminuria and preserving glomerular filtration for patients with chronic kidney disease and type 2 diabetes, according to study data presented...
www.medpagetoday.com
New Guidelines on GLP-1 Drugs for Obesity Released
Agents should not replace a healthy diet and physical activity, WHO document says
www.nbcnews.com
Novo Nordisk still sees potential for GLP-1 drugs for Alzheimerās, despite trial setback
GLP-1 drugs, which include Ozempic and Wegovy, have becomeĀ one of the most closely watched experimental approachesĀ for slowing Alzheimerās ā a disease with few treatment options.
reut.rs
Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment
Details from two large trials of Novo Nordisk's GLP-1 drug semaglutide showed it provided no cognitive benefit for people with early Alzheimer's disease, researchers said at a medical meeting on Wednesday, dashing remaining hopes that the widely used medication could help such patients.
www.mirror.co.uk
'I lost 4st on weight loss jabs but it ruined Christmas'
reut.rs
Novo Nordisk gears up for December Ozempic launch in India, sources say
Danish drugmaker Novo Nordisk will launch its blockbuster diabetes drug Ozempic in India this month, three sources familiar with the matter said, as it seeks to strengthen its foothold in the world's most populous nation.
mailchi.mp
Global Health NOW 12.03.25
A New Era for GLP-1 Drugs; and The Toxic Toll of Battery Recycling
J. Offir, PhD@joffirphd.bsky.social
2/ dogs in this race, either benefiting from your weight loss goals & other New Year's rssolutions, or trying to get in your way to protect their own profits. This article mentions several winners & losers in the GLP-1 craze: š¹ļøPharmacies: look for more supplements (like, to combat GLP-1...
bit.ly
The Bounce-Back Effect: What Happens After Cessation of Low-Dose Semaglutide in People with HIV
Short-term, low-dose, semaglutide was associated with initial cardiometabolic benefit, but rapid weight regain and some loss of cardiometabolic benefit occ
westvirginiawatch.com
States retreat from covering drugs for weight loss ā¢ West Virginia Watch
Some states are rethinking their coverage of GLP-1 drugs for weight loss as budgets tighten and Medicaid programs brace for cuts.
bit.ly
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Abstract. The approvals of semaglutide and tirzepatide have set new benchmarks in the treatment of type 2 diabetes and obesity. Building on their success,
www.washingtonpost.com
Ozempic is changing how we spend money and time, plus what we eat
As peopleās bodies change because of GLP-1s, so does their spending across industries including fashion, restaurants, gyms and travel.
missouriindependent.com
States retreat from covering drugs for weight loss ā¢ Missouri Independent
Some states are rethinking their coverage of GLP-1 drugs for weight loss as budgets tighten and Medicaid programs brace for the cuts included in President Donald Trumpās broad tax and spending law.
reut.rs
Novo Nordisk justifies reasoning behind failed GLP-1 Alzheimer's trials
Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans, animals and real-world findings, a top company executive said on Tuesday, acknowledging criticism that Novo's studies had design flaws.
www.aamc.org
Are GLP-1 weight-loss drugs safe for older adults?
These blockbuster medications have been associated with a range of health benefits, but a lack of data about how the drugs impact adults age 65 and up has clini
www.npr.org
Brain scientists are seeking weight-loss drugs without the nausea
Weight-loss drugs like Wegovy and Zepbound often cause nausea and other side effects. Brain scientists are looking for ways to solve this problem.
Medsky Topics 
